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Purpose: The aim of this study is to evaluate the ability of transit dosimetry using commercial treatment planning
system (TPS) and an electronic portal imaging device (EPID) with simple calibration method to verify the beam
delivery based on detection of large errors in treatment room.
Methods and materials: Twenty four fields of intensity modulated radiotherapy (IMRT) plans were selected from
four lung cancer patients and used in the irradiation of an anthropomorphic phantom. The proposed method was
evaluated by comparing the calculated dose map from TPS and EPID measurement on the same plane using a
gamma index method with a 3% dose and 3 mm distance-to-dose agreement tolerance limit.
Results: In a simulation using a homogeneous plastic water phantom, performed to verify the effectiveness of the
proposed method, the average passing rate of the transit dose based on gamma index was high enough, averaging
94.2% when there was no error during beam delivery. The passing rate of the transit dose for 24 IMRT fields was lower
with the anthropomorphic phantom, averaging 86.8% ± 3.8%, a reduction partially due to the inaccuracy of TPS
calculations for inhomogeneity. Compared with the TPS, the absolute value of the transit dose at the beam center
differed by −0.38% ± 2.1%. The simulation study indicated that the passing rate of the gamma index was significantly
reduced, to less than 40%, when a wrong field was erroneously irradiated to patient in the treatment room.
Conclusions: This feasibility study suggested that transit dosimetry based on the calculation with commercial TPS and
EPID measurement with simple calibration can provide information about large errors for treatment beam delivery.
Keywords: Transit dose, EPID, Intensity modulated radiation therapy, Gamma indexIntroduction
The goal of radiotherapy is to deliver a therapeutic dose to
a tumor volume while minimizing doses to surrounding
organs [1-3]. Efforts to achieve this goal have led to in-
creasingly complex radiation delivery and dose calcula-
tion algorithms. In addition, more advanced treatment
techniques, including intensity-modulated radiotherapy
(IMRT), helical tomotherapy (TOMO), volumetric modu-
lated arc therapy (VMAT) and heavy ion therapy, have
been developed to overcome the disadvantages of conven-
tional three-dimensional conformal radiotherapy (3D-
CRT). Although highly technological treatment methods* Correspondence: radioyoon@korea.ac.kr
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unless otherwise stated.are important to achieve the goal of radiotherapy, these
methods can be useless or even harmful to patients if the
therapeutic dose is not accurately delivered as planned.
For example, an IMRT planning error in New York in
2005 caused a fatal radiation overdose resulting in the
death of the patient [4]. This accident suggests that accur-
ate verification of the dose delivered to the patient is es-
sential for maximum treatment efficacy and to prevent
accidental overdoses.
Accidental exposure during radiotherapy may be
avoided by learning from previous accidents [4-7]. Most
of these accidents were due to human errors, includingd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Patient characteristics, prescribed radiation dose
and fraction size






1 19 6 32 6400
2 31 6 27 5400
3 57 6 33 6600
4 23 6 34 6800
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dures, all of which should be expected. These kinds of er-
rors may be prevented by the application of several types
of preventive actions during radiation treatment. One of
the most important is patient-specific quality assurance
(QA), which is generally performed to assure that there is
no difference between the dose calculated by the TPS and
the actual measured dose. Conventional patient-specific
QA for IMRT involves measuring the absolute dose as
well as measuring the two-dimensional dose distribution
using a homogeneous phantom. EPID based portal dosim-
etry has recently become popular for patient-specific
IMRT dose verification in radiotherapy, although EPID isFigure 1 Pictures of the experimental setup and axial views of IMRT
anthropomorphic phantom, (c) a homogeneous plastic phantom and (d) athe primary tool used to verify patient positioning in the
treatment room [8,9].
Good agreement based on conventional QA, however,
does not guarantee the accuracy of the actual dose dis-
tribution to the patient in the treatment room. In gen-
eral, unexpected errors during beam delivery are difficult
to detect by conventional QA, since the latter is basically
pretreatment verification. A possible approach to detect
errors during treatment is a transit dosimetry acquired
using EPID in the treatment room. So far, various stud-
ies have been carried out for the transit dosimetry at the
position of the EPID behind a patient [10-15]. Among
them the use of the TPS can be considered as one of the
simple ways to conduct the 2D transit dosimetry since
the transit dose is easily calculated by commercial soft-
ware. McNutt et al. used the convolution/superposition
method to predict the dose at the level of imaging device
and found that the calculated doses at the EPID level
were within 4% of the measured doses in the central re-
gion of the field [13]. More recently, Reich et al. investi-
gated the calculation of transit dose maps using
commercial TPS (Pinnacle Version 6.2b, Phillips Medical
System, Milpitas, USA) and reported that the calculatedcalculations maps. (a) a homogeneous plastic phantom, (b) an
n anthropomorphic phantom.
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maps showing less than 2% of dose difference on the
central beam axis [11].
Although the previous studies showed that 2D transit dos-
imetry based on TPS calculation and EPID measurement is
simple and advantageous, more studies are needed for
this method due to several reasons. First, the accurate
calibration of EPID for various factors is still too com-
plex to be adapted easily in clinic. Second, as time goes
on, various TPSs are available and the algorithm of TPS
becomes more accurate. Therefore, it is meaningful to
test the recent TPS for the use of transit dosimetry.
Third, only limited clinical cases were examined in pre-
vious studies suggesting the need of more research for
the use of TPS in 2D transit dosimetry. In this study,
we used EPID to measure the transit dose passing
through an anthropomorphic phantom in the treatment
room based on simple calibration method and evalu-
ated the ability of transit dosimetry using commercial
TPS to verify the beam delivery during treatment in
radiotherapy.Figure 2 Experimental setup for EPID and dose calibration. (a) EPID ca
function of EPID in calibrated units and (c) dose conversion factor for EPIDMethods and materials
We evaluated 24 IMRT fields used in the radiotherapy of
4 randomly selected lung cancer patients (see Table 1).
All IMRT QA was carried out with the sliding window
technique, after modifying the gantry angles of all treat-
ment fields to 0 degrees. The patient-specific planned
dose distributions were calculated using the Eclipse
treatment planning system Version 8.0.3 (Varian Medical
Systems, Salt Lake City, UT, USA) with AAA algorithm.
Figure 1(a) and (b) show pictures of the experimental
setup with a homogeneous solid water phantom (Plastic
Water, New York, USA) and an inhomogeneous an-
thropomorphic phantom (Rando, NY, USA), respect-
ively. Using the CT (LightSpeed RT16 CT-Simulator,
GE Healthcare, Milwaukee, WI, USA) scanned phan-
tom, an IMRT QA plan used for transit dosimetry was
made in the TPS for selected fields. Figure 1(c) and (d)
show examples of the axial view of the transit dose
passing through a homogeneous plastic water phantom
and anthropomorphic phantom, respectively, as calcu-
lated by the TPS.libration with ion chamber measurement, (b) radiation dose as a
signals and CU.
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were calculated by Eclipse TPS. To do that, we first built
the artificial phantom (see arrows in Figure 1(c), (d)) at
the location of EPID from TPS and ran the calculation
to get the dose map in the EPID plane. In the treatment
room, the radiation fields of the IMRT QA plans were
delivered using a Varian Clinac iX linear accelerator
(Varian Medical Systems, Palo Alto, CA) equipped with
an aS1000 EPID. The EPID system is an amorphous
silicon flat panel imager, with an active imaging area of
30 × 40 cm2 with a matrix size of 1024 × 768 pixels.
For image acquisition and transit dose analysis, the
EPID was first calibrated according to the vendor’s guide-
lines with dark field, flood field and the diagonal profile
correction which was measured at dmax in water for a
40 × 40 cm2 open field. Then, EPID response was scaled
such that 1 Calibrated Unit (CU) corresponds to 100 MU
delivered by a 10 × 10 cm2 open field at 100 cm source-to-
detector distance (SDD). It has been reported that the
mechanical parts of the EPID produces a non-uniform
back scattering in Varian EPID [16]. To remove the
non-uniform backscattering pattern in calibration process,
the impact of the backscatter that was present during
the flood-field calibration was deduced and, then, theFigure 3 Transit dose comparisons for fields 1 and 5 of patient 2. (a) fie
phantom, (c) field 1 with an anthropomorphic phantom and (d) field 5 witestimated non-uniform back-scatter pattern is cor-
rected [17]. The absolute dose of the transit beam was
first measured with EPID in calibrated units (CU) and
converted to the absorbed dose. Figure 2(a) shows the
experimental setup for EPID calibration with ion chamber
measurement where we used 10 × 10 cm2 field size and
20 cm-thick homogeneous phantom as a simple approxi-
mation of field size and patient thickness, respectively.
Both Eclipse calculation and measurement were done in
8 mm depth [8]. To convert the CU to dose, the calibra-
tion curve was acquired by comparison between dose
measured by ion chamber and CU measured by EPID sig-
nal. Figure 2(b) shows that CU vs. dose on the beam axis
as a function of CU (i.e., beam-on time). Although it
seems like there is a linear relationship between dose and
CU, the relationship is non-linear at low CU values.
Figure 2(c) shows that the absorbed dose per CU decreases
as the CU values increases and then it becomes relatively
constant. Using this conversion factor, the measured EPID
signal was converted to the absorbed dose. The data pro-
duced by the TPS and EPID were compared using the RIT
113 software module (Radiological Imaging Technol-
ogy, Ver. 5.2, Colorado Springs, CO, USA) which usu-
ally takes less than 3 seconds for each field.ld 1 with a homogeneous phantom, (b) field 5 with a homogeneous
h an anthropomorphic phantom.
Table 2 Gamma index (3%/3 mm)-based passing rates for transit dose measured with an homogeneous phantom
Patient 1 (%) Patient 2 (%) Patient 3 (%) Patient 4 (%)
Field 1 92.6 (8.6 × 7 cm2) 96.6 (6.8 × 4.5 cm2) 92.0 (8.6 × 6.1 cm2) 95.6 (6.6 × 5 cm2)
Field 2 92.7 (8.3 × 7 cm2) 95.5 (6.3 × 4.8 cm2) 95.0 (7.8 × 6.3 cm2) 95.1 (6.3 × 5 cm2)
Field 3 90.8 (8.7 × 7 cm2) 95.7 (6.6 × 4.8 cm2) 96.5 (6.6 × 6.3 cm2) 95.6 (5.6 × 5 cm2)
Field 4 91.3 (9.3 × 7 cm2) 95.3 (6.6 × 4.8 cm2) 93.6 (6.5 × 6.3 cm2) 95.3 (5.9 × 5 cm2)
Field 5 92.7 (8.6 × 7 cm2) 95.4 (7.1 × 4.8 cm2) 93.1 (8.3 × 6.1 cm2) 95.4 (6.6 × 5 cm2)
Field 6 91.9 (8.6 × 7 cm2) 97.4 (6.3 × 4.8 cm2) 90.1 (8.3 × 6.1 cm2) 95.8 (5.8 × 5 cm2)
Mean 92.0 96.0 93.4 95.4
SD 0.8 0.9 2.2 0.3
Parenthesis under the passing rates denotes the collimator (jaw) size of each beam.
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dose distributions with 3% dose difference and 3 mm
distance-to-agreement (DTA) criteria [18]. The gamma
index (GI) value of a point on the image can be calcu-
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denotes the difference in dose at each position [18].
Results
The effectiveness of the proposed method was first evalu-
ated using a 20 cm-thick homogeneous plastic phantom.
Figure 3(a) and (b) show the GI maps of transit doses
passing through a homogeneous solid water phantom
for fields 1 and 5 of patient 2 in Table 1, respectively.
The passing rates were 96.6% and 95.4%, respectively,
indicating that the transit dose map measured with theTable 3 Comparison of absolute and relative transit doses me
anthropomorphic phantom
Field Patient 1 Patient 2
ADD (%) RDP (%) ADD (%) RDP (%
Field 1 −1.1 83.3 −1.4 84.9
Field 2 −0.8 85.7 2.2 90.3
Field 3 −4.0 89.5 −1.4 87.9
Field 4 0.6 82.2 −0.7 82.4
Field 5 −1.3 83.6 1.0 94.4
Field 6 −2.2 79.3 0.2 81.8
Mean −1.5 83.9 0.0 86.9
SD 1.5 3..4 1.4 4.9
Abbreviations: ADD absolute dose difference, defined as percentage dose difference
index (3%/3 mm)-based passing rate.EPID is well matched with the dose distribution calcu-
lated by the TPS. This finding suggested that the
gamma index-based comparison of measured and TPS
calculated transit dose can be used to prevent accidents
in radiotherapy since the passing rate will decrease sig-
nificantly if errors occur during treatment. That is, the
proposed method can effectively assess the errors of the
treatment plan at the final stage (i.e., in the treatment
room). Table 2 shows the detailed passing rate for the
24 IMRT fields, revealing an average normal beam de-
livery of 94.2%.
GI analysis of the calculated transit doses for fields 1
and 5 of patient 2 using the anthropomorphic phantom,
however, showed more regions with GI greater than 1, in-
dicating an increased percentage of failure (Figure 3(c),
(d)). The passing rates were decreased to 84.9% and
94.4%, respectively. Detailed gamma analysis of transit
dosimetry with anthropomorphic phantoms showed that
the passing rates are generally decreased, to a mean ± SD
of 86.8% ±3.8% (Table 3). Table 3 also shows the absolute
dose difference (ADD) at the beam center between the
TPS calculated and EPID measured values. The mean ±
SD percentage difference was −0.38% ± 2.1%, showing that
the absorbed doses of the transit beam measured with the
EPID were close to the doses calculated by the TPS.asured with EPID and the lung region of an
Patient 3 Patient 4
) ADD (%) RDP (%) ADD (%) RDP (%)
0.1 87.0 −1.4 86.6
3.9 87.2 −0.6 86.7
0.5 88.8 1.1 88.9
−1.2 87.3 −5.1 92.2
−3.3 91.2 3.5 93.8
0.8 80.4 1.7 87.8
0.1 87.0 −0.1 89.3
2.4 3.6 3.0 3.0
at the beam center, RDP relative dose passing rate (RDP), defined as gamma
Table 4 Comparison of relative transit doses measured with EPID and the pelvic region of an anthropomorphic
phantom
Field 1 Field 2 Field 3 Field 4 Field 5 Field 6 Mean
Passing rate (%) of patient 1 96.6 90.7 90.3 93.1 89.8 90.5 91.8
Passing rate (%) of patient 2 93.9 95.1 93.6 94.6 94.0 92.6 94.0
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thropomorphic phantoms comes from the inaccuracy of
TPS calculations for inhomogeneity and the limitations
of the analysis of the measurement results, ignoring a
number of correction factors. To prove whether inaccur-
acy of the heterogeneity correction algorithm in Eclipse
is more dominant in causing the observed deviations be-
tween measured and predicted dose distributions for
lung treatments, additional experiments in the pelvic re-
gion of the anthropomorphic phantom was carried out.
Table 4 shows the passing rates about the IMRT fields
from patient 1 and 2. As seen in Table 4, the passing
rates are much higher than the values in Table 3 but
lower than the values in Table 2. This result suggests
that, although the calculation algorithm of the TPS
worked well for the homogeneous phantom, its accuracy
was reduced for inhomogeneous material.Figure 4 Simulation results for change in gamma index when erroneo
(a) Field 2 of patient 1, (b) field 2 of patient 2, (c) field 2 of patient 3 and (Discussion
We have measured the transit doses of 24 IMRT fields
with EPID and compared them with the doses calculated
from the TPS. Comparisons of absolute doses with the
anthropomorphic phantom showed good agreement be-
tween measured and calculated doses at the beam cen-
ter. Although the relative doses of the measured and
calculated transit beams passing through a homogeneous
phantom were well matched, the average passing rate
was reduced to 86.8% when using an inhomogeneous an-
thropomorphic phantom.
In general, the EPID response is a function of various
factors such as field size, phantom thickness, lateral scatter
in the EPID, phantom-to-EPID scatter and the measured
dose will generally have relatively large uncertainties if one
omits corrections for all these effects. The dependence of
EPID response on various factors and correspondingusly choosing wrong fields rather than field 1 of patient 2.
d) field 2 of patient 4.
Table 5 Gamma index (3%/3 mm)-based passing rates
for transit dose measured with EPID and an
anthropomorphic phantom following selection of the
wrong fields instead of field 1 of patient 2
Fields Patient number
Patient 1 (%) Patient 2 (%) Patient 3 (%) Patient 4 (%)
Field 1 20.5 - 32.4 38.4
Field 2 24.4 35.9 25.5 35.5
Field 3 31.0 49.7 30.1 49.3
Field 4 18.9 32.9 16.9 29.0
Field 5 35.0 37.8 14.9 21.6
Field 6 22.1 32.2 15.6 31.5
Mean 25.3 37.7 22.6 34.2
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extensively by Nijsten et al. [19]. Although many research
groups have reported and suggested the calibration
methods of EPID for various factors, it is still too complex
to apply this method clinically and need more simple way
to do it. Our experimental results suggest that, based on
the TPS and EPID measurement with simple calibration,
we can monitor (or verify) whether the desired beam (or
dose fluence) was delivered to the patient without large
error during treatment. If one is interested in detection
for this kind of large error, rough calibration of EPID
seems to work well.Figure 5 Flow chart for the verification of radiotherapy beam in the tTo evaluate whether the proposed transit dosimetry
is feasible in detecting large errors during treatment,
we deliberately delivered radiation to the wrong IMRT
fields and evaluated changes in transit dose distribution
(Figure 4). For example, when field 2 of patient 2 was
erroneously irradiated with the dose planned for field 1
of patient 2, the passing rate of the gamma index was
decreased to 35.9% (Figure 4(b)). This result would thus
show an error in beam delivery since the passing rate
would be too low compared with normal beam delivery.
Table 5 shows the passing rates when either the wrong
patient or the wrong field was chosen erroneously.
Choosing the wrong fields significantly decreased the
GI passing rate for the transit dose, to an average of
30.0%. These findings indicate that transit dosimetry
can be used to detect beam delivery errors since
changes in transit dose passing through a patient can
be easily detected.
Figure 5 shows an example of flow chart for the treat-
ment beam monitoring using comparisons of the transit
dose. The first step is to obtain calculated and measured
dose maps from TPS and EPID, respectively. This is
followed by defining a common rectangular region of
interest (ROI) for later comparison of dose correlations.
In the next step, doses are compared based on gamma
index (GI) analysis. If these comparisons pass the prede-
fined tolerance value, the treatment proceeds to the next
field; if not, the treatment should be stopped and the
reason for the mismatch should be verified. Althoughreatment room using comparisons of transit doses.
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ment as a future study since the EPID signal should be
converted to absorbed dose using actual treatment field
size and patient thickness.
Conclusion
We have compared EPID measurements of transit dose
for 24 IMRT fields with doses calculated from TPS. Our
feasibility study suggests that EPID based transit dose
monitoring in the treatment room can provide informa-
tion about the accuracy of beam delivery.
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